Last reviewed · How we verify
NCT07379177
Evaluation of the Pharmacokinetics of Curcumin Capsules in Healthy Human
NA trial testing Curcumin in Healthy in 12 participants. Not yet recruiting.
7 February 2026
Quick facts
| Lead sponsor | Kingdomway (Inner Mongolia) Nutritional Food Co., Ltd. |
|---|---|
| Phase | NA |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | none |
| Primary purpose | other |
| Enrollment | 12 |
| Start date | 28 January 2026 |
| Primary completion | 7 February 2026 |
| Estimated completion | 28 February 2026 |
| Sites | 1 location across China |
Drugs / interventions tested
- Curcumin (CURCUMIN) — full drug profile →
- Nanocurcumin
Conditions studied
- Healthy — all drugs for Healthy →
Sponsor
Kingdomway (Inner Mongolia) Nutritional Food Co., Ltd.
Who can join
Adults 18 to 65, any sex, with Healthy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Main objective: Through blood drug concentration testing, evaluate the post-meal pharmacokinetic characteristics of the curcumin product compared to similar products, and assess the differences in body exposure between the self-developed product and the control product in healthy trial participants. Secondary objective: Observe the safety of the self-developed product and the control product in healthy trial participants. Study population: Healthy male individuals or non-pregnant non-lactating females
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07379177
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Curcumin
Trials testing the same drug.
- NCT07436130 — Curcumin in Critically Ill Patients With Sepsis · NA · not yet recruiting
- NCT07251985 — Cognitive Effects of Bioavailable Curcumin · Phase 2 · not yet recruiting
- NCT07523256 — Effect of Curcumin Add-On Therapy on Quality of Life and IL-1β Levels in Patients With Schizophrenia · NA · completed
- NCT06531863 — Curcumin and EGCG Supplementation to Improve Serum BDNF and Mood Disturbance · EARLY_PHASE1 · recruiting
- NCT06312761 — Single-Dose Pharmacokinetics of Oral Testosterone Undecanoate With and Without Concomitant Inhibition of UGT2B17 · Phase 1, PHASE2 · unknown
Other recruiting trials for Healthy
Currently open trials in the same condition.
- NCT06707207 — Predicting Future Errors During Skill Performance · recruiting
- NCT07169630 — PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI) · Phase 1 · recruiting
- NCT07499414 — The Effects of the Bile Acid Supplement, 7-keto Lithocholic Acid, on Human Gut Microbiota and Risk Factors for Disease. · NA · recruiting
- NCT07496697 — Effects of Electroacupuncture at NP82 and SP15 on Bowel Motility in Healthy Subjects · NA · recruiting
- NCT06431932 — Pilot Trial of Fisetin in Healthy Volunteers and Older Patients With Multimorbidity · Phase 1, PHASE2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07379177 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Kingdomway (Inner Mongolia) Nutritional Food Co., Ltd.
- Last refreshed: 30 January 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07379177.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing